AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet